InsiderTrades.com logo
The Next Step of Their Control Is Here …
From Weiss Ratings   |   Ad
Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.
4 simple steps to protect your privacy and money before it’s too late.
Elias D. Papadimas net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Elias Papadimas Biography and Net Worth

CAO of Exicure
Elias D. Papadimas is the Chief Accounting Officer at Exicure Inc.

How do I contact Elias D. Papadimas?

The corporate mailing address for Mr. Papadimas and other Exicure executives is 2430 N. Halsted St., Chicago IL, 60614. Exicure can also be reached via phone at (847) 673-1700 and via email at [email protected]. Learn More on Elias D. Papadimas' contact information.

Has Elias D. Papadimas been buying or selling shares of Exicure?

Elias D. Papadimas has not been actively trading shares of Exicure during the last quarter. Learn More on Elias D. Papadimas' trading history.

Are insiders buying or selling shares of Exicure?

In the last twelve months, insiders at the sold shares 1 times. They sold a total of 3,400,000 shares worth more than $4,488,000.00. The most recent insider tranaction occured on February, 29th when Major Shareholder Co. Ltd. Dgp sold 3,400,000 shares worth more than $4,488,000.00. Insiders at Exicure own 3.9% of the company. Learn More about insider trades at Exicure.

Information on this page was last updated on 2/29/2024.

Elias D. Papadimas Insider Trading History at Exicure

See Full Table

Elias D. Papadimas Buying and Selling Activity at Exicure

This chart shows Elias D. Papadimas's buying and selling at Exicure by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Exicure Company Overview

Exicure logo
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Read More

Today's Range

Now: $0.50
Low: $0.50
High: $0.53

50 Day Range

MA: $0.62
Low: $0.51
High: $0.74

2 Week Range

Now: $0.50
Low: $0.36
High: $1.50

Volume

28,216 shs

Average Volume

378,182 shs

Market Capitalization

$4.33 million

P/E Ratio

0.30

Dividend Yield

N/A

Beta

1.31
The Next Step of Their Control Is Here …
From Weiss Ratings   |   Ad
Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.
4 simple steps to protect your privacy and money before it’s too late.